References
- Dzięgielewska-Gęsiak S, Fatyga E, Piłot M, Wierzgoń A, Muc-Wierzgoń M. Are there differences in gut microbiome in patients with type 2 diabetes treated by metformin or metformin and insulin. Diabetes Metab Syndr Obes. 2022;15:3589–3599. doi:10.2147/DMSO.S377856
- Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2021;14(1):166. doi:10.3390/nu14010166
- Doestzada M, Vila AV, Zhernakova A, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018;9(5):432‐445. doi:10.1007/s13238-018-0547-2
- Chávez-Carbajal A, Pizano-Zárate ML, Hernández-Quiroz F, et al. Characterization of the gut microbiota of individuals at different T2D stages reveals a complex relationship with the host. Microorganisms. 2020;8(1):94. doi:10.3390/microorganisms8010094
- Kyriachenko Y, Falalyeyeva T, Korotkyi O, Molochek N, Kobyliak N. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes. 2019;10(3):154–168. doi:10.4239/wjd.v10.i3.154